Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 289

1.

Isolation and genomic analysis of circulating tumor cells from castration resistant metastatic prostate cancer.

Magbanua MJ, Sosa EV, Scott JH, Simko J, Collins C, Pinkel D, Ryan CJ, Park JW.

BMC Cancer. 2012 Feb 28;12:78. doi: 10.1186/1471-2407-12-78.

2.

Genomic profiling of isolated circulating tumor cells from metastatic breast cancer patients.

Magbanua MJ, Sosa EV, Roy R, Eisenbud LE, Scott JH, Olshen A, Pinkel D, Rugo HS, Park JW.

Cancer Res. 2013 Jan 1;73(1):30-40. doi: 10.1158/0008-5472.CAN-11-3017. Epub 2012 Nov 7.

3.

Circulating tumor cell analysis in patients with progressive castration-resistant prostate cancer.

Shaffer DR, Leversha MA, Danila DC, Lin O, Gonzalez-Espinoza R, Gu B, Anand A, Smith K, Maslak P, Doyle GV, Terstappen LW, Lilja H, Heller G, Fleisher M, Scher HI.

Clin Cancer Res. 2007 Apr 1;13(7):2023-9.

4.

Quantitative characterization of androgen receptor protein expression and cellular localization in circulating tumor cells from patients with metastatic castration-resistant prostate cancer.

Reyes EE, VanderWeele DJ, Isikbay M, Duggan R, Campanile A, Stadler WM, Vander Griend DJ, Szmulewitz RZ.

J Transl Med. 2014 Nov 26;12:313. doi: 10.1186/s12967-014-0313-z.

5.

Chromosomal Instability Estimation Based on Next Generation Sequencing and Single Cell Genome Wide Copy Number Variation Analysis.

Greene SB, Dago AE, Leitz LJ, Wang Y, Lee J, Werner SL, Gendreau S, Patel P, Jia S, Zhang L, Tucker EK, Malchiodi M, Graf RP, Dittamore R, Marrinucci D, Landers M.

PLoS One. 2016 Nov 16;11(11):e0165089. doi: 10.1371/journal.pone.0165089. eCollection 2016.

6.

Isolation of circulating tumor cells by immunomagnetic enrichment and fluorescence-activated cell sorting (IE/FACS) for molecular profiling.

Magbanua MJ, Park JW.

Methods. 2013 Dec 1;64(2):114-8. doi: 10.1016/j.ymeth.2013.07.029. Epub 2013 Jul 26.

PMID:
23896286
7.

Whole Genomic Copy Number Alterations in Circulating Tumor Cells from Men with Abiraterone or Enzalutamide-Resistant Metastatic Castration-Resistant Prostate Cancer.

Gupta S, Li J, Kemeny G, Bitting RL, Beaver J, Somarelli JA, Ware KE, Gregory S, Armstrong AJ.

Clin Cancer Res. 2017 Mar 1;23(5):1346-1357. doi: 10.1158/1078-0432.CCR-16-1211. Epub 2016 Sep 6.

PMID:
27601596
8.

Molecular profiling of tumor cells in cerebrospinal fluid and matched primary tumors from metastatic breast cancer patients with leptomeningeal carcinomatosis.

Magbanua MJ, Melisko M, Roy R, Sosa EV, Hauranieh L, Kablanian A, Eisenbud LE, Ryazantsev A, Au A, Scott JH, Park JW.

Cancer Res. 2013 Dec 1;73(23):7134-43. doi: 10.1158/0008-5472.CAN-13-2051. Epub 2013 Oct 18.

9.

Genomic high-resolution profiling of single CKpos/CD45neg flow-sorting purified circulating tumor cells from patients with metastatic breast cancer.

Neves RP, Raba K, Schmidt O, Honisch E, Meier-Stiegen F, Behrens B, Möhlendick B, Fehm T, Neubauer H, Klein CA, Polzer B, Sproll C, Fischer JC, Niederacher D, Stoecklein NH.

Clin Chem. 2014 Oct;60(10):1290-7. doi: 10.1373/clinchem.2014.222331.

10.

Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer.

Attard G, Swennenhuis JF, Olmos D, Reid AH, Vickers E, A'Hern R, Levink R, Coumans F, Moreira J, Riisnaes R, Oommen NB, Hawche G, Jameson C, Thompson E, Sipkema R, Carden CP, Parker C, Dearnaley D, Kaye SB, Cooper CS, Molina A, Cox ME, Terstappen LW, de Bono JS.

Cancer Res. 2009 Apr 1;69(7):2912-8. doi: 10.1158/0008-5472.CAN-08-3667.

11.

Fluorescence in situ hybridization analysis of circulating tumor cells in metastatic prostate cancer.

Leversha MA, Han J, Asgari Z, Danila DC, Lin O, Gonzalez-Espinoza R, Anand A, Lilja H, Heller G, Fleisher M, Scher HI.

Clin Cancer Res. 2009 Mar 15;15(6):2091-7. doi: 10.1158/1078-0432.CCR-08-2036. Epub 2009 Mar 10.

12.

Androgen receptor expression on circulating tumor cells in metastatic breast cancer.

Fujii T, Reuben JM, Huo L, Espinosa Fernandez JR, Gong Y, Krupa R, Suraneni MV, Graf RP, Lee J, Greene S, Rodriguez A, Dugan L, Louw J, Lim B, Barcenas CH, Marx AN, Tripathy D, Wang Y, Landers M, Dittamore R, Ueno NT.

PLoS One. 2017 Sep 28;12(9):e0185231. doi: 10.1371/journal.pone.0185231. eCollection 2017.

13.

Functional phenotyping and genotyping of circulating tumor cells from patients with castration resistant prostate cancer.

Paris PL, Kobayashi Y, Zhao Q, Zeng W, Sridharan S, Fan T, Adler HL, Yera ER, Zarrabi MH, Zucker S, Simko J, Chen WT, Rosenberg J.

Cancer Lett. 2009 May 18;277(2):164-73. doi: 10.1016/j.canlet.2008.12.007. Epub 2009 Jan 21.

PMID:
19162393
14.

Detection of androgen receptor mutations in circulating tumor cells in castration-resistant prostate cancer.

Jiang Y, Palma JF, Agus DB, Wang Y, Gross ME.

Clin Chem. 2010 Sep;56(9):1492-5. doi: 10.1373/clinchem.2010.143297. Epub 2010 Jun 25.

15.

Rapid phenotypic and genomic change in response to therapeutic pressure in prostate cancer inferred by high content analysis of single circulating tumor cells.

Dago AE, Stepansky A, Carlsson A, Luttgen M, Kendall J, Baslan T, Kolatkar A, Wigler M, Bethel K, Gross ME, Hicks J, Kuhn P.

PLoS One. 2014 Aug 1;9(8):e101777. doi: 10.1371/journal.pone.0101777. eCollection 2014.

16.

A three-marker FISH panel detects more genetic aberrations of AR, PTEN and TMPRSS2/ERG in castration-resistant or metastatic prostate cancers than in primary prostate tumors.

Qu X, Randhawa G, Friedman C, Kurland BF, Glaskova L, Coleman I, Mostaghel E, Higano CS, Porter C, Vessella R, Nelson PS, Fang M.

PLoS One. 2013 Sep 30;8(9):e74671. doi: 10.1371/journal.pone.0074671. eCollection 2013.

17.

Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer.

Azad AA, Volik SV, Wyatt AW, Haegert A, Le Bihan S, Bell RH, Anderson SA, McConeghy B, Shukin R, Bazov J, Youngren J, Paris P, Thomas G, Small EJ, Wang Y, Gleave ME, Collins CC, Chi KN.

Clin Cancer Res. 2015 May 15;21(10):2315-24. doi: 10.1158/1078-0432.CCR-14-2666. Epub 2015 Feb 23.

18.

Circulating tumor cells in localized prostate cancer: isolation, cultivation in vitro and relationship to T-stage and Gleason score.

Kolostova K, Broul M, Schraml J, Cegan M, Matkowski R, Fiutowski M, Bobek V.

Anticancer Res. 2014 Jul;34(7):3641-6.

PMID:
24982381
19.

Common structural and epigenetic changes in the genome of castration-resistant prostate cancer.

Friedlander TW, Roy R, Tomlins SA, Ngo VT, Kobayashi Y, Azameera A, Rubin MA, Pienta KJ, Chinnaiyan A, Ittmann MM, Ryan CJ, Paris PL.

Cancer Res. 2012 Feb 1;72(3):616-25. doi: 10.1158/0008-5472.CAN-11-2079. Epub 2011 Dec 7.

20.

Functional characterization of circulating tumor cells with a prostate-cancer-specific microfluidic device.

Kirby BJ, Jodari M, Loftus MS, Gakhar G, Pratt ED, Chanel-Vos C, Gleghorn JP, Santana SM, Liu H, Smith JP, Navarro VN, Tagawa ST, Bander NH, Nanus DM, Giannakakou P.

PLoS One. 2012;7(4):e35976. doi: 10.1371/journal.pone.0035976. Epub 2012 Apr 27. Erratum in: PLoS One. 2012;7(7): doi/10.1371/annotation/9d3d22ed-dc5a-4484-9254-1584864f4aac.

Supplemental Content

Support Center